Terms: = Lung cancer AND MSI2, ENSG00000153944, 124540 AND Prognosis
3 results:
1. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract] [Full Text] [Related]
2. Myofibroblast-Specific msi2 Knockout Inhibits HCC Progression in a Mouse Model.
Qu C; He L; Yao N; Li J; Jiang Y; Li B; Peng S; Hu K; Chen D; Chen G; Huang W; Cao M; Fan J; Yuan Y; Ye W; Hong J
Hepatology; 2021 Jul; 74(1):458-473. PubMed ID: 33609283
[TBL] [Abstract] [Full Text] [Related]
3. Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
Ichikawa T; Saruwatari K; Mimaki S; Sugano M; Aokage K; Kojima M; Hishida T; Fujii S; Yoshida J; Kuwata T; Ochiai A; Suzuki K; Tsuboi M; Goto K; Tsuchihara K; Ishii G
Lung Cancer; 2017 Nov; 113():134-139. PubMed ID: 29110840
[TBL] [Abstract] [Full Text] [Related]
